The development of accurate and reproducible immune monitoring assays is essential to determine the immune responses in patients receiving novel immune therapies and ultimately transitioning these therapies from the clinical trial phase to standard of care. The goal of the Translational Immunology Section (TIS) is to develop cutting edge immune monitoring technology that will be made available to all NIAMS investigators.
The Translational Immunology Section provides NIAMS scientists with:
- Services, consultative advice and in-depth instructions in a variety of immunologic methods to facilitate their interpretation of immunoassays most relevant to a particular clinical trial or to study a particular patient.
- State-of-the-art immunoassays such as multicolor flow cytometry and Luminex, enabling NIAMS clinicians to monitor the immune responses of their clinical trial patients.
- Analysis of a reference population to define baseline responses, ensuring quality control checks that will validate the reproducibility of these results.